Officer Jeffrey S. Heier proposes selling 10,869 Ocular Therapeutix (Nasdaq: OCUL) shares.
Ocular Therapeutix officer Jeffrey S. Heier has proposed selling 10,869 common shares of OCUL, with an aggregate market value of $76,639.49. The shares are from restricted stock vesting under a registered plan on October 1, 2026, with an approximate sale date of October 2, 2026. Heier also previously sold 3,296 common shares for $35,532.20 on August 24, 2026.
Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny
Ocular Therapeutix (OCUL) has seen a 144.6% stock gain over three years, but its current P/S ratio of 30.8x is significantly higher than the industry average of 4.5x, raising concerns about its valuation. Despite the upcoming NDA submission for its AXPAXLI program in late 2026, analysts and valuation models suggest the stock is overvalued given its current sales and ongoing losses. The article explores whether the company's growth prospects justify its current high price.
Ocular Therapeutix Price Target Maintained With a $23.00/Share by Chardan Capital
Chardan Capital has maintained its price target for Ocular Therapeutix (NASDAQ: OCUL) at $23.00 per share. This rating indicates a continued positive outlook from the firm regarding the company's stock performance.
Can Ocular Therapeutix (OCUL) Justify Its Price On Sales?
Ocular Therapeutix (OCUL) has experienced a sharp pullback in its share price this year despite a strong three-year run, prompting investors to scrutinize its valuation against its sales profile. The company's P/S ratio of 30.8x is significantly higher than the Pharmaceuticals industry average of 4.5x, suggesting overvaluation according to the fair multiple model. While positive regulatory progress for AXPAXLI and plans for a potential 2027 launch exist, the current valuation heavily penalizes the company for losses and execution risk.
Chardan Capital maintains Buy rating on Ocular Therapeutix, $23 price target
Chardan Capital has reiterated its Buy rating for Ocular Therapeutix with a price target of $23.00, suggesting a significant upside. The positive outlook is driven by the company's strong clinical pipeline, including AXPAXLI for wet AMD, and confidence in its innovative hydrogel technology for sustained drug release. Other analysts also show strong support for OCUL, with price targets ranging from $18 to $25.
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
Shares of Ocular Therapeutix (OCUL) dropped significantly, heading for its worst week since April 2024, after competitors Kodiak Sciences and 4D Molecular Therapeutics released positive clinical trial updates for their longer-lasting eye injection treatments for Wet AMD. Despite this, Ocular Therapeutix still plans to file for approval of its lead drug, AXPAXLI, in Q4 2026, with analysts suggesting the current valuation is overdone given its potential sales. Retail traders remain bullish on OCUL, with some speculating about a potential buyout due to its perceived undervaluation.
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
Ocular Therapeutix (OCUL) stock is experiencing its worst week in 2.5 years following positive clinical trial updates from rivals Kodiak Sciences and 4D Molecular Therapeutics for wet age-related macular degeneration (Wet AMD) treatments. While competitors demonstrated advancements in longer-lasting eye injections and gene therapy, Ocular Therapeutix still plans to file for approval of its lead drug, AXPAXLI, in Q4 2026. Despite the stock drop, analysts believe the valuation is undervalued given the drug's potential, and retail sentiment remains "extremely bullish."
RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential
RBC Capital has reiterated an Outperform rating and $30 price target for Ocular Therapeutix (NASDAQ: OCUL), believing the recent stock sell-off is overdone. The firm highlights Ocular Therapeutix's lead candidate, axpaxli, as a potentially best-in-class long-acting treatment for wet age-related macular degeneration (wAMD) with potential for biannual or annual dosing, targeting a $1 billion sales peak. The company is set to file for FDA approval in Q4 2026, with a potential launch by Q4 2027.
RBC Capital reiterates Ocular Therapeutix stock rating on wAMD treatment potential
RBC Capital has reiterated an Outperform rating and a $30.00 price target for Ocular Therapeutix (NASDAQ:OCUL), despite a recent stock sell-off. The firm believes the sell-off is overdone and that Ocular Therapeutix's axpaxli, a potential long-acting treatment for wet age-related macular degeneration (wAMD), is well-positioned to capture a significant market share. The drug is expected to be filed for approval in Q4 2026 and could generate approximately $1 billion in sales within three to four years post-launch.
ETFs Investing in Ocular Therapeutix Inc Stocks
This article provides a comprehensive list of ETFs that hold Ocular Therapeutix Inc (0OT) stocks, sorted by market value. It details various funds, including those from BlackRock, Invesco, Vanguard, and State Street, along with their market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify ETFs with Ocular Therapeutix exposure, making stock investing more accessible and offering diversified opportunities.
Did Positive FDA Meeting Just Shift Ocular Therapeutix Stock Investment Narrative?
Ocular Therapeutix completed a positive Pre-NDA Meeting with the FDA for AXPAXLI for wet AMD, confirming plans for an NDA filing in Q4 2026. This development signals progress towards their first potential large retinal product and reduces some regulatory uncertainty, though key risks like future FDA review or safety follow-up remain. The company's investment narrative now focuses on executing the NDA submission and managing costs while still unprofitable.
Precision Trading with Ocular Therapeutix Inc. (OCUL) Risk Zones
This article provides a detailed analysis of Ocular Therapeutix Inc. (OCUL) for precision trading, highlighting weak sentiment across all horizons and suggesting a short bias. It outlines institutional trading strategies including position, momentum breakout, and risk hedging, complete with entry, target, and stop-loss zones. The analysis also features multi-timeframe signal analysis and an exceptional 65.3:1 risk-reward setup.
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Ocular Therapeutix (NASDAQ:OCUL) is on track to file for FDA approval of AXPAXLI in Q4 2026 for wet age-related macular degeneration, based on positive SOL-1 Phase 3 results and safety data from the SOL-R study. The company aims for a 2027 commercial launch and has sufficient funding into 2028. AXPAXLI, a tyrosine kinase inhibitor, is intended to reduce the burden of frequent injections and has shown promising results in preventing vision loss and maintaining rescue-free status in patients.
Ocular Therapeutix, Inc. (OCUL) Stock Price, News, Quote & History
This article provides a detailed financial overview of Ocular Therapeutix, Inc. (OCUL), including its current stock price, recent news, and key financial statistics. It offers data such as market capitalization, trading ranges, and profitability metrics, alongside related company insights and research reports. The page also features a chart for historical stock performance.
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Ocular Therapeutix plans to submit a U.S. marketing application for AXPAXLI in Q4 of this year for wet age-related macular degeneration (wet AMD), following successful alignment with the FDA based on data from its SOL-1 Phase 3 trial and safety data from the ongoing SOL-R study. The company anticipates a potential 2027 commercial launch and believes it has met all necessary evidentiary standards for a single-trial submission. Ocular Therapeutix also highlighted promising results in diabetic retinopathy from the HELIOS study and noted its strong cash position, funding it into 2028.
Ocular Therapeutix reports positive pre-NDA FDA meeting for AXPAXLI
Ocular Therapeutix successfully completed a pre-NDA meeting with the FDA for AXPAXLI (OTX-TKI), its investigational candidate for wet age-related macular degeneration (AMD). The company remains on track to submit the NDA in Q4 2026. If approved, AXPAXLI could become the first TKI commercialized for wet AMD, potentially offering superior durability with infrequent dosing.
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and $25.00 price target for Ocular Therapeutix (NASDAQ:OCUL) following the company's successful Pre-New Drug Application (Pre-NDA) meeting with the FDA for its drug candidate AXPAXLI. The company is on track to submit the NDA in Q4 2026 for wet age-related macular degeneration, with analyst sentiment remaining strong despite a recent stock dip. InvestingPro analysis highlights upward earnings revisions and a strong financial position for Ocular Therapeutix.
Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI
Ocular Therapeutix has completed its Pre-New Drug Application meeting with the FDA for AXPAXLI, an investigational treatment for wet age-related macular degeneration. The company plans to submit the NDA in the fourth quarter of 2026, based on promising efficacy and safety data from its Phase 3 trials. The submission will leverage the 505(b)(2) pathway, potentially accelerating the FDA review process.
Ocular Therapeutix completes pre-NDA meeting with FDA for AXPAXLI By Investing.com
Ocular Therapeutix, Inc. announced the completion of its Pre-New Drug Application (NDA) meeting with the FDA for AXPAXLI, an investigational treatment for wet age-related macular degeneration. The company plans to submit the NDA in the fourth quarter of 2026, based on Phase 3 trial data, and will utilize the 505(b)(2) pathway to potentially shorten the FDA review timeline. AXPAXLI is also being evaluated for diabetic retinal disease.
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Ocular Therapeutix announced a positive Pre-NDA meeting with the U.S. FDA for AXPAXLI™ (OTX-TKI) in wet age-related macular degeneration, keeping the company on track for a Q4 2026 New Drug Application submission. The FDA aligned with an NDA package based on Phase 3 SOL-1 efficacy and safety data, interim SOL-R safety data, and confirmatory evidence supporting repeat dosing. The submission will utilize the 505(b)(2) pathway, which could shorten the FDA review timeline by up to 60 days.
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in several upcoming investor and scientific conferences in September and October 2026. The company will engage in investor one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference and present a fireside chat at the Baird 2026 Global Healthcare Conference. Additionally, Ocular Therapeutix will participate in multiple scientific meetings, including The Retina Society 59th Annual Scientific Meeting, Ophthalmology Futures Forums Retina Forum 2026, Euretina Innovation Spotlight, and the 26th Euretina Congress, where they will present data on their investigational product AXPAXLI (OTX-TKI) for neovascular age-related macular degeneration.
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in several upcoming investor and scientific conferences in September and October 2026. The company will engage in investor one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference and host a fireside chat at the Baird 2026 Global Healthcare Conference. Additionally, Ocular Therapeutix will present data on its investigational product AXPAXLI™ (OTX-TKI) for neovascular age-related macular degeneration at The Retina Society 59th Annual Scientific Meeting, Ophthalmology Futures Forums Retina Forum 2026, Euretina Innovation Spotlight, and the 26th Euretina Congress.
This Insider Has Just Sold Shares In Ocular Therapeutix
The article reports that an insider has sold shares in Ocular Therapeutix. No further details regarding the identity of the insider, the number of shares sold, or the reasons for the sale are provided in the given content.
The FDA Alignment Playbook Behind Ocular Therapeutix’s Single-Trial NDA
Ocular Therapeutix successfully developed a regulatory strategy for its lead asset, AXPAXLI, leading to a single registrational trial NDA under a Special Protocol Assessment. This success is attributed to early and continuous alignment with the FDA's Division of Ophthalmology, which has a history of leadership consistency. The company leveraged the Special Protocol Assessment to secure regulatory certainty for its trial design while repositioning a second study for commercial advantage.
Ocular Therapeutix CSO Sanjay Nayak Executes 1,897-Share Sell-to-Cover Transaction Under Rule 10b5-1 Plan
Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, Inc. (NASDAQ: OCUL), sold 1,897 shares of common stock on August 24, 2026. This transaction, executed under a Rule 10b5-1 plan, was a sell-to-cover to satisfy tax withholding requirements related to the vesting of restricted stock units. After the sale, Nayak directly holds 326,898 shares of Ocular Therapeutix common stock.
Ocular Therapeutix CEO Dugel sells $233,159 in shares
Pravin Dugel, CEO of Ocular Therapeutix (NASDAQ:OCUL), sold 21,649 shares for $233,159 to cover tax obligations from vested restricted stock units. This "sell-to-cover" transaction was pre-planned, and Dugel still directly holds over 2.5 million shares, with an additional 744,903 shares held indirectly through a trust for which he is the beneficiary. The company is also in a dynamic period, with an upcoming NDA submission for AXPAXLI, positive analyst ratings, and increased options trading activity following a rival's trial setback.
Ocular Therapeutix CSO Sanjay Nayak sells $20,449 in shares
Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, sold 1,897 shares worth $20,449 to cover tax obligations related to restricted stock unit vesting. Following the sale, Nayak still directly owns 326,898 shares. The stock is currently trading below its 52-week high, and InvestingPro suggests it is undervalued with a fair value of $11.34.
Ocular Therapeutix (OCUL) Could Be 60% Below Fair Value As Axpaxli Story Builds
Ocular Therapeutix (OCUL) is considered significantly undervalued, trading at US$10.78 against a narrative fair value of US$27.09. This undervaluation is largely due to the anticipated approval of AXPAXLI, a potential wet AMD product with superior dosing intervals, which could capture substantial market share and drive revenue growth. While the market currently assigns a high P/S ratio, the company's future relies heavily on Axpaxli's success and avoiding setbacks in trials or pricing pressure.
Ocular Therapeutix (NASDAQ: OCUL) officer to sell 1,897 shares
An officer at Ocular Therapeutix (NASDAQ: OCUL), Sanjay Nayak, plans to sell 1,897 shares of common stock, valued at approximately $20,452.70, originating from restricted stock vesting. This is reported via a Rule 144 SEC filing. The filing also indicates that Nayak previously sold 1,858 shares on May 26, 2026, for $15,236.53.
Ocular Therapeutix (NASDAQ: OCUL) insider plans 3,296-share sale
Jeffrey S. Heier, an insider at Ocular Therapeutix (OCUL), plans to sell 3,296 common shares with an aggregate market value of $35,532.20. This sale is associated with restricted stock vesting under a registered plan and will be handled by Morgan Stanley Smith Barney LLC. The filing also indicates that Heier previously sold 3,018 common shares for $24,745.19 within the prior three months.
Ocular Therapeutix (NASDAQ: OCUL) insider plans 21,649-share sale
An officer at Ocular Therapeutix (NASDAQ: OCUL), Pravin Dugel, has filed a Form 144 indicating a planned sale of 21,649 shares of common stock, associated with restricted stock vesting on August 22, 2026. The proposed sale has an approximate market value of $233,185.71. Additionally, the filing reveals that Dugel sold 21,156 shares in the prior three months, generating aggregate proceeds of $173,513.05.
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
Ocular Therapeutix (OCUL) saw its stock rise by 10.4% after reporting stronger-than-expected Q2 results and providing an update on its AXPAXLI Phase 3 trials. The company's pivotal retinal asset, AXPAXLI, remains on track for an FDA-aligned NDA submission in Q4 2026, bolstering investor confidence despite the company's reliance on this single asset and ongoing losses. The positive Week 52 SOL-1 topline data for AXPAXLI, highlighting its durability and safety, supports management's confidence in the regulatory pathway.
Ocular Therapeutix (OCUL) Could Be 59% Undervalued Following Earnings Beat And AXPAXLI Progress
Ocular Therapeutix (OCUL) recently reported strong Q2 results, surpassing analyst expectations, and is making significant progress with its AXPAXLI phase 3 trials, aiming for an NDA in Q4 2026. The stock is considered 59.1% undervalued, with a fair value of $27.09, driven by the potential of AXPAXLI to capture a large market share in wet AMD. However, the valuation depends heavily on trial outcomes, regulatory decisions, and managing higher spending and dilution.
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
The article reviews the Q2 earnings season for the pharmaceuticals industry, highlighting Ocular Therapeutix (OCUL) as a strong performer with flat year-on-year revenue that still beat analyst expectations. It also discusses Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) for strong Q2 results, while noting Zoetis (ZTS) had a weaker quarter despite a slight stock increase. The industry as a whole saw revenues beat estimates by 5.4%, with stock prices up 5% on average.
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix Inc. (NASDAQ: OCUL) stock is trading higher on Monday after its rival, EyePoint Inc. (NASDAQ: EYPT), released underwhelming Phase 3 trial data for its wet AMD treatment. EyePoint's Duravyu failed to meet its primary visual acuity endpoint, which analysts believe validates Ocular Therapeutix's own wet AMD treatment, Axpaxli (OTX-TKI). William Blair analysts noted that despite differences in trial design, EyePoint's data supports Axpaxli's profile as a durable and effective treatment, reducing risk for Ocular Therapeutix's ongoing studies and potential FDA approval.
OCUL Stock Climbs As FDA Clears Path For AXPAXLI NDA
Ocular Therapeutix Inc. (OCUL) stock climbed by 8.12% after the FDA agreed that a single successful Phase 3 SOL-1 trial, combined with safety data, is sufficient for an AXPAXLI wet AMD New Drug Application (NDA) via the 505(b)(2) pathway. The company reported a Q2 2026 net loss of $0.35 per share and $13.5M in revenue, slightly beating consensus, and has a cash runway into 2028. This regulatory de-risking and promising post-hoc SOL-1 data, suggesting a significant reduction in injection burden for wet AMD patients, are key drivers for investor optimism and analyst reiterations of Outperform ratings.
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
EyePoint Pharmaceuticals (EYPT) shares plummeted after its wet AMD treatment, Duravyu, failed its primary endpoint in a Phase 3 trial, putting the stock on track for a 16-month low. In contrast, rival Ocular Therapeutix (OCUL) saw its shares surge as its SOL-1 Phase 3 trial for a similar condition met its primary endpoint, leading retail investors to consider OCUL a stronger buyout candidate. Despite the primary endpoint miss, Duravyu met several secondary goals, and EyePoint anticipates results from a second Phase 3 trial in Q4 2026.
Ocular Therapeutix stock rises as rival’s wet AMD trial stumbles
Ocular Therapeutix Inc (NASDAQ:OCUL) shares rose after its competitor EyePoint Pharmaceuticals (NASDAQ:EYPT) announced that its DURAVYU treatment failed to meet the primary endpoint in a Phase 3 wet AMD trial. EyePoint's trial showed that DURAVYU did not achieve the primary endpoint of visual acuity change versus aflibercept, although an ad hoc analysis excluding a small cohort of patients suggested non-inferiority. Both companies are developing extended-release treatments for retinal diseases like wet AMD, aiming to reduce the frequency of injections.
OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210
This article provides detailed financial and analytical data for Ocular Therapeutix Inc (OCUL), including its live stock price, chart, news, and a comprehensive stock score. It covers key financial figures, performance over various periods, technical analysis, analyst ratings, and company profile. The data shows OCUL currently trades at $10.040, with analysts giving it a "Buy" rating and a target price significantly higher than its current value.
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued?
Ocular Therapeutix (OCUL) is under investor scrutiny after reporting wider losses and filing a shelf registration for potential future stock issuance, causing recent share price fluctuations. Despite being down year-to-date, the stock is considered significantly undervalued by some analysts, primarily due to the anticipated approval of AXPAXLI for wet AMD. However, the company's valuation remains heavily dependent on trial outcomes and future funding needs.
Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at Zacks Research
Zacks Research upgraded Ocular Therapeutix (NASDAQ:OCUL) from a "strong sell" to a "hold" rating. Despite this change, the consensus among analysts remains a "Moderate Buy" with an average price target of $25.75, reflecting broad positive sentiment. The company recently reported better-than-expected quarterly results, with institutional investors increasing their stakes, although insiders have sold a small number of shares.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement awards to Ms. Beth Rada, the new SVP, Government Affairs and Public Policy. These awards, consisting of stock options and restricted stock units, are material to her employment acceptance under Ocular’s 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants vest over several years, contingent on her continued service to the company.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to Ms. Beth Rada, the new SVP of Government Affairs and Public Policy. These awards, consisting of stock options and restricted stock units, were granted under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) to induce her employment. The grants vest over several years, contingent on her continued service to the company.
Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option
Ocular Therapeutix (NASDAQ: OCUL) has granted its new SVP, Government Affairs and Public Policy, Beth Rada, inducement equity awards under its 2019 Inducement Stock Incentive Plan. These awards, effective August 10, 2026, include a non-statutory option to purchase up to 85,000 shares at $9.24 per share, vesting over four years, and 28,000 restricted stock units vesting in three equal annual installments. The grants are intended to incentivize Ms. Rada's employment and are in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to Ms. Beth Rada, the new SVP, Government Affairs and Public Policy, effective August 10, 2026. These awards, consisting of stock options and restricted stock units, were made under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of Ms. Rada's employment inducement and are subject to vesting schedules and continued service to the company.
Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued?
Ocular Therapeutix (OCUL) is under investor scrutiny following wider quarterly losses and a new shelf registration filing, which could lead to future stock dilution. Despite a recent share price rebound, the stock remains down year-to-date. The company's valuation is heavily tied to the potential approval of its wet AMD product, AXPAXLI, with varying fair value estimates from analysts and internal models.
Dimensional Fund Advisors LP Takes $5.49 Million Position in Ocular Therapeutix, Inc. $OCUL
Dimensional Fund Advisors LP has initiated a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL), purchasing 649,756 shares valued at approximately $5.49 million. This move is part of broader institutional interest, with hedge funds and other institutional investors collectively owning 59.21% of the biopharmaceutical company's stock. Analysts generally maintain a "Moderate Buy" rating for OCUL, with a consensus target price of $25.75, following the company's recent earnings beat.
Janus Henderson Group PLC Has $581,000 Holdings in Ocular Therapeutix, Inc. $OCUL
Janus Henderson Group PLC significantly reduced its stake in Ocular Therapeutix by 98.4% in the first quarter, now holding 68,500 shares valued at $581,000. Despite this, institutional investors collectively own 59.21% of the company. Ocular Therapeutix reported better-than-expected Q1 earnings, with a loss of $0.35 per share against an estimated $0.40, and revenue slightly above forecasts, though the company remains unprofitable.
Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company significantly increased its stake in Ocular Therapeutix (NASDAQ:OCUL) by 145.9% in the first quarter, now owning 227,808 shares. This acquisition is part of a broader trend of institutional investment, with hedge funds and institutional investors collectively owning 59.21% of the biopharmaceutical company's stock. Despite a recent insider stock sale, analysts maintain a "Moderate Buy" consensus rating for OCUL, with an average target price of $25.75 against its current $9.19 share price.
The debate of durability in nAMD
This article discusses the evolving focus in treating wet age-related macular degeneration (AMD) from efficacy to durability. It highlights the importance of reducing treatment burden for patients, caregivers, and physicians, while also emphasizing that "rescue-free rates" and "time-to-first-rescue" are more meaningful measures of durability than just reduced injection frequency. The authors argue that a comprehensive assessment of new therapies must consider all patient interventions and how sustained disease control is achieved without additional interventions.
